Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson Hospital

June 23, 2026 updated by: M.D. Anderson Cancer Center
The main rationale underlying this study is that prostate cancer clinical trials are lacking representation from racial and ethnic minority groups. Study proposal aims to target barriers at the participant, investigator, and health system level through specific interventions to increase the percentage of participants from these backgrounds on cancer clinical trials.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Primary Objectives:

The study objective is to increase the number of participants on prostate cancer clinical trials at LBJ. Investigators will complete several objectives:

  • To design a culturally tailored video highlighting participant narratives and determine its impact on participants' decision-making pertaining to joining a clinical trial
  • To conduct educational sessions with frontline oncology providers
  • To coordinate participant care through utilization of a nurse navigator
  • To evaluate the effectiveness of this multi-pronged intervention to increase enrollment onto two prostate cancer clinical trials and compare enrollment and one-year retention rates before and after the intervention

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77090
        • Recruiting
        • The University of Texas M. D. Anderson Cancer Center
        • Contact:
        • Principal Investigator:
          • Debanjan Pain, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

These criteria include diagnosed prostate cancer patients receiving care at LBJ Hospital who

Are eligible for an open prostate cancer clinical trial at LBJ Hospital during the study period

Can provide informed consent.

Exclusion Criteria:

These criteria include prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition or have a medical condition that prevents participation in the trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Video Intervention to Prostate Cancer Patient
The interventions will be conducted at Lyndon B. Johnson (LBJ) Hospital, a safety net facility that cares for a majority Latino and/or Black patient population.
Other: Video
Participants will watch a short video in clinic. Participants will complete the two validated scales before and after viewing the video.
Experimental: To Conduct Educational Sessions with Frontline Oncology Providers
The investigator will conduct multiple one-hour educational sessions focused on participant-centered communication and cultural competency with the 42 oncology fellows during their academic half-days. Fellows attending the educational sessions will be invited to complete a Likert-style course evaluation form and provide open-ended feedback."
Other: Video
Participants will watch a short video in clinic. Participants will complete the two validated scales before and after viewing the video.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and Adverse Events (AEs)
Time Frame: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Through study completion; an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Debanjan Pain, MD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 26, 2026

Primary Completion (Estimated)

January 31, 2028

Study Completion (Estimated)

January 31, 2030

Study Registration Dates

First Submitted

December 29, 2025

First Submitted That Met QC Criteria

May 13, 2026

First Posted (Actual)

May 18, 2026

Study Record Updates

Last Update Posted (Actual)

June 26, 2026

Last Update Submitted That Met QC Criteria

June 23, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-1431
  • NCI-2025-09179 (Other Identifier: NCI-CTRP Clinical Trials Registry)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe